MedTrace Logo

Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer

NCT00547339 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 94

Last updated 2022-12-07

Study results available
· View outcomes & findings →

Summary

RATIONALE: Stereotactic body radiation therapy may be able to send x-rays directly to the tumor and cause less damage to normal tissue.

PURPOSE: This phase I/II trial is studying the side effects and best dose of stereotactic body radiation therapy and to see how well it works in treating patients with prostate cancer.

Conditions

Interventions

RADIATION

stereotactic body radiation therapy (SBRT)- 45 Gy

Dose of SBRT - 45 Gray (Gy) in five fractions

RADIATION

stereotactic body radiation therapy (SBRT) - 47.5 Gy

Dose of SBRT - 47.5 Gray (Gy) in five fractions

RADIATION

stereotactic body radiation therapy (SBRT) - 50 Gy (Phase 1)

RADIATION

stereotactic body radiation therapy (SBRT) - 50 Gy (Phase 2)

Sponsors & Collaborators

  • University of Texas Southwestern Medical Center

    lead OTHER

Principal Investigators

  • Robert D. Timmerman, MD · Simmons Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
120 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-07-31
Primary Completion
2014-07-20
Completion
2022-11-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00547339 on ClinicalTrials.gov